IDH1 and cholangiocarcinoma: A recent multicentre, randomised, double-blind, placebo-controlled, Phase 3 study (ClarIDHy) demonstrated that progression-free and overall survival were significantly improved with ivosidenib, a small-molecule targeted inhibitor of mutated IDH1, in patients with previously treated IDH1-mutant CCA compared to placebo and subsequently received FDA approval (reference ID: 442715) [11, 12].